HomeBUSINESS
BUSINESS

FDA Accepts sNDA for Lenvima’s HCC Indication
(Sep.27.2017)

Eisai said on September 26 that the US FDA has accepted for review a supplemental new drug application (sNDA) for its cancer drug Lenvima (lenvatinib) for an additional indication of hepatocellular carcinoma (HCC) potentially in the first-line setting ...
(LOG IN FOR FULL STORY)

News Calendar